Research Vision:

My primary goal is focused towards clinical translation of adenovirus-based therapeutics.

Research Areas:

• Establishing Oncolytic Adenovirus as a mighty expression vector for cancer therapy and imaging

• Gene therapy

• Developing transgenic pig models for oncolytic virus therapy and cancer research

Research Publications:

1. Robertson, MG.; Eidenschink, BB.; Iguchi, E.; Zakharkin, S. O.; LaRocca, C. J.; Tolosa, E. J.; Truty, M. J.; Jacobsen, K.; Fernandez-Zapico, M. E.; Davydova, J., Cancer imaging and therapy utilizing a novel NIS-expressing adenovirus: The role of adenovirus death protein deletion. Mol Ther Oncolytics 2021, 20, 659-668

2. Koodie L, Robertson MG, Chandrashekar M, Ruth G, Dunning M, Bianco RW, Davydova J. Rodents Versus Pig Model for Assessing the Performance of Serotype Chimeric Ad5/3 Oncolytic Adenoviruses. Cancers (Basel). 2019 Feb 8;11(2):198. doi: 10.3390/cancers11020198. PMID: 30744019; PMCID: PMC6406826.

3. Salzwedel AO, Han J, LaRocca CJ, Shanley R, Yamamoto M, Davydova J. Combination of interferon-expressing oncolytic adenovirus with chemotherapy and radiation is highly synergistic in hamster model of pancreatic cancer. Oncotarget. 2018 Apr 6;9(26):18041-18052. doi: 10.18632/oncotarget.24710. PMID: 29719589; PMCID: PMC5915056.

4. LaRocca CJ, Han J, Gavrikova T, Armstrong L, Oliveira AR, Shanley R, Vickers SM, Yamamoto M, Davydova J. Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment of pancreatic cancer. Surgery. 2015 May;157(5):888-98. doi: 10.1016/j.surg.2015.01.006. Epub 2015 Feb 27. PMID: 25731784; PMCID: PMC4417428.

5. Davydova J, Le LP, Gavrikova T, Wang M, Krasnykh V, Yamamoto M. Infectivity-enhanced cyclooxygenase-2-based conditionally replicative adenoviruses for esophageal adenocarcinoma treatment. Cancer Res. 2004 Jun 15;64(12):4319-27. doi: 10.1158/0008-5472.CAN-04-0064. PMID: 15205347.